SHANDONG BOAN BIOTECH.H 1
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, … Read more
SHANDONG BOAN BIOTECH.H 1 (UJ9) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SHANDONG BOAN BIOTECH.H 1 (UJ9) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SHANDONG BOAN BIOTECH.H 1 - Net Assets Trend (None–None)
This chart illustrates how SHANDONG BOAN BIOTECH.H 1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SHANDONG BOAN BIOTECH.H 1 (None–None)
The table below shows the annual net assets of SHANDONG BOAN BIOTECH.H 1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SHANDONG BOAN BIOTECH.H 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SHANDONG BOAN BIOTECH.H 1 Competitors by Market Cap
The table below lists competitors of SHANDONG BOAN BIOTECH.H 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PNGJL
NSE:PNGJL
|
$145.62 Million |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
$145.66 Million |
|
British American Tobacco Malaysia Bhd
KLSE:4162
|
$145.66 Million |
|
Halk Gayrimenkul Yatirim Ortakligi AS
IS:HLGYO
|
$145.70 Million |
|
Solara Active Pharma Sciences Limited
NSE:SOLARA
|
$145.55 Million |
|
Gigasolar Materials
TWO:3691
|
$145.51 Million |
|
Nordrest Holding AB (publ)
ST:NREST
|
$145.50 Million |
|
Pendrell Corp
PINK:PCOA
|
$145.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANDONG BOAN BIOTECH.H 1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SHANDONG BOAN BIOTECH.H 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANDONG BOAN BIOTECH.H 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SHANDONG BOAN BIOTECH.H 1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANDONG BOAN BIOTECH.H 1 (UJ9) | €- | N/A | N/A | $145.58 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |